哥本哈根指数与ROMA在卵巢恶性肿瘤术前风险分层中的比较:越南首个前瞻性队列研究
该前瞻性队列纳入475例卵巢肿块患者,比较CPH-I与ROMA术前预测卵巢癌的诊断性能。两者判别能力相似(AUC分别为0.898和0.882,p>0.05),CPH-I最佳截断值1.89%时敏感度87.1%、特异度78.5%,ROMA敏感度74.2%、特异度91.8%。CPH-I可不分绝经状态作为ROMA的简单替代。
要点
- CPH-I与ROMA对卵巢癌术前预测的AUC分别为0.898与0.882,差异无统计学意义。
- CPH-I最佳截断值1.89%时敏感度87.1%、特异度78.5%,ROMA分别为74.2%和91.8%。
- CPH-I可不分绝经状态用于卵巢肿瘤恶性风险分层,效力与ROMA相似。
核心结论
- CPH-I与ROMA在卵巢癌术前预测中判别性能相似,CPH-I可作为不分绝经状态的简单替代工具。
研究设计与样本
- 前瞻性队列研究,2018年1月至2020年6月越南两家医院纳入475例经妇科检查/超声诊断的卵巢肿块住院患者。
- 基于血清CA-125和HE4计算ROMA与CPH-I,最终诊断依据临床、影像与组织学,并记录FIGO 2014分期。
主要发现
- 475例中良性肿瘤408例、交界性肿瘤5例、恶性肿瘤62例。
- ROMA与CPH-I判别性能相似,差异无统计学意义(p>0.05)。
- ROMA敏感度74.2%、特异度91.8%;CPH-I敏感度87.1%、特异度78.5%。
- CPH-I最佳截断值为1.89%。
- ROMA的AUC为0.882(95%CI:0.849-0.909),CPH-I的AUC为0.898(95%CI:0.867-0.924)。
关键数值与推荐
- CPH-I最佳截断值1.89%时敏感度87.1%、特异度78.5%。
- ROMA敏感度74.2%、特异度91.8%。
- CPH-I的AUC为0.898(95%CI:0.867-0.924),ROMA的AUC为0.882(95%CI:0.849-0.909)。
临床怎么用
- CPH-I可不分绝经状态用于卵巢肿瘤术前恶性风险分层,效力与ROMA相似。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to evaluate the diagnostic performances of the Copenhagen Index (CPH-I) and Risk of Ovarian Malignancy Algorithm (ROMA) in the preoperative prediction of ovarian cancer. METHODS: In a prospective cohort study, data were collected from 475 patients with ovarian masses diagnosed by gynecologic examination / ultrasound who were hospitalized at the Departments of Obstetrics and Gynecology, Hue University of Medicine and Pharmacy Hospital and Hue Central Hospital, Vietnam, between January 2018 and June 2020. ROMA and CPH-I were calculated based on measurements of serum carbohydrate antigen (CA-125) and human epididymis protein (HE4). The final diagnosis was based on clinical features, radiologic and histologic findings, and the International Federation of Gynecology and Obstetrics (FIGO) 2014 stages of ovarian cancer were recorded. Matching the values of ROMA and CPH-I to postoperative histopathology reports resulted in the preoperative prediction values. RESULTS: Among the 475 women, 408 had benign tumors, 5 had borderline tumors and 62 had malignant tumors. The two indices showed similar discriminatory performances with no significant differences (p > 0.05). At an optimal cut-off, the sensitivities/specificities of ROMA and CPH-I for ovarian cancer diagnosis were 74.2% and 91.8%, 87.1% and 78.5%, respectively. The optimal cut-off for CPH-I was 1.89%. The areas under the ROC curves (AUCs) of ROMA and CPH-I were 0.882 (95% CI: 0.849-0.909) and 0.898 (95% CI: 0.867-0.924), respectively. CONCLUSIONS: The introduction of the Copenhagen Index to help stratify the malignancy risk of ovarian tumors, irrespective of menopausal status, might be applied as a simple alternative with a similar efficacy to ROMA in clinical practice.
引用
- Tran DT, Vo VK, Le MT, et al. Copenhagen Index versus ROMA in preoperative ovarian malignancy risk stratification: Result from the first Vietnamese prospective cohort study. Gynecol Oncol. 2021. PMID: 33994145. doi:10.1016/j.ygyno.2021.05.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。